Fennec Pharmaceuticals Inc.

Name: Fennec Pharmaceuticals Inc. standardized financial statements, quarterly
Creator: Listed

FENCNasdaqCIK 1211583HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$17.9m, Q2 FY2026

Operating income$1.7m, Q2 FY2026

Net income$2.0m, Q2 FY2026

Fennec Pharmaceuticals Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	6.5	9.7	25.4	7.3	7.0	7.9	8.8	9.7	12.5	13.8	15.1	17.9
Cost of revenue	$m	0.3	0.7	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Gross profit	$m	6.2	9.1	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Research and development	$m	0.0	0.0	0.0	0.2	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.1
Operating income	$m	(1.0)	(1.8)	13.7	(5.0)	(5.2)	(0.9)	(0.8)	(2.7)	(0.2)	(2.6)	(0.1)	1.7
Interest expense	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Income tax	$m	not reported	not reported	not reported	not reported	not reported	not reported	0.0	0.0	not reported	not reported	not reported	0.0
Net income	$m	(1.9)	(2.7)	12.8	(5.6)	(5.7)	(2.0)	(1.2)	(3.2)	(0.6)	(4.8)	0.2	2.0
Diluted EPS	$ per share	(0.07)	not reported	0.41	(0.20)	(0.21)	not reported	(0.04)	(0.11)	(0.02)	not reported	0.01	0.05
Basic EPS	$ per share	(0.07)	not reported	0.47	(0.20)	(0.21)	not reported	(0.04)	(0.11)	(0.02)	not reported	0.01	0.06

Balance sheet

Cash and equivalents$41.2m, Q2 FY2026

Long-term debt$19.4m, Q3 FY2025

Shareholders' equity$42.4m, Q2 FY2026

Fennec Pharmaceuticals Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	12.4	13.3	51.2	43.1	40.3	26.6	22.7	18.7	21.9	36.8	40.2	41.2
Current assets	$m	19.9	26.9	68.2	62.2	58.0	44.1	43.0	40.8	46.1	67.0	66.9	72.5
Total assets	$m	20.0	26.9	69.2	63.2	58.9	44.9	46.4	44.9	49.3	70.6	71.8	75.8
Current liabilities	$m	3.9	7.6	9.8	7.7	7.4	6.9	8.4	8.4	9.8	10.5	9.6	12.4
Total liabilities	$m	29.6	38.5	66.2	64.5	64.1	50.8	52.3	52.3	53.8	35.1	34.1	33.3
Long-term debt	$m	25.6	30.9	31.3	31.8	32.1	19.3	19.4	19.4	19.4	not reported	not reported	not reported
Current portion of debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	(10.5)	(11.6)	3.0	(1.4)	(5.2)	(5.9)	(5.9)	(7.5)	(4.5)	35.5	37.7	42.4

Cash flow

Operating cash flow$50.0k, Q2 FY2026

Fennec Pharmaceuticals Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(2.8)	(4.9)	39.0	(8.4)	(2.2)	(1.5)	(4.3)	(3.7)	1.5	(6.0)	2.4	0.1
Capital expenditure	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)36.43m, Q2 FY2026

Fennec Pharmaceuticals Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	26.1	26.6	26.5	26.6	31.1	27.3	27.4	27.6	27.7	27.9	35.5	36.4

Shares outstanding: 35.07m at Aug 11, 2026, from the cover of the 10-Q filed Aug 13, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. Listed shows no prices and gives no investment advice.